NYSE:MEDMedifast Stock Price, Forecast & News

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED shares have increased by 132.0% and is now trading at $163.42.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medifast.

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Medifast.

Medifast Inc (NYSE:MED) posted its quarterly earnings data on Wednesday, August, 5th. The specialty retailer reported $1.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.84 by $0.12. Medifast had a return on equity of 69.77% and a net margin of 10.04%.
View Medifast's earnings history.

Medifast announced a quarterly dividend on Tuesday, June 16th. Stockholders of record on Tuesday, June 30th will be paid a dividend of $1.13 per share on Thursday, August 6th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date is Monday, June 29th.
View Medifast's dividend history.

4 Wall Street analysts have issued twelve-month price objectives for Medifast's shares. Their forecasts range from $86.00 to $220.00. On average, they anticipate Medifast's stock price to reach $132.00 in the next twelve months. This suggests that the stock has a possible downside of 19.2%.
View analysts' price targets for Medifast.

Headlines about MED stock have trended very positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Medifast.

Medifast saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 1,830,000 shares, a drop of 39.2% from the June 30th total of 3,010,000 shares. Based on an average trading volume of 284,500 shares, the days-to-cover ratio is currently 6.4 days. Currently, 16.3% of the shares of the company are sold short.
View Medifast's Current Options Chain.

Some companies that are related to Medifast include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Boeing (BA), Mastercard (MA), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Paypal (PYPL) and Baidu (BIDU).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include Principal Financial Group Inc. (1.68%), Ingalls & Snyder LLC (0.45%), Robeco Institutional Asset Management B.V. (0.40%), WINTON GROUP Ltd (0.36%), Chickasaw Capital Management LLC (0.26%) and Russell Investments Group Ltd. (0.24%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, SG Americas Securities LLC, Bridge City Capital LLC, First Trust Advisors LP, Chickasaw Capital Management LLC, Matisse Capital, Nisa Investment Advisors LLC, and MBM Wealth Consultants LLC. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast.

MED stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Mackay Shields LLC, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., Parallel Advisors LLC, Icon Advisers Inc. Co., Arizona State Retirement System, and Spearhead Capital Advisors LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer.
View insider buying and selling activity for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MED stock can currently be purchased for approximately $163.42.

Medifast has a market capitalization of $1.93 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]